Floatz logo

FILGRASTIM

Recurrent Colon Cancer

National Cancer Institute (NCI)protein_peptidePhase 2Dormant
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
48/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Recurrent Colon Cancer cohort.

Asset / SponsorPhaseRating
FLUOROURACILUM
Akeso
Phase 4A
(+)-VINCRISTINE
City of Hope Medical Center
Phase 3BBB
Irinotecan
Fudan University
Phase 3BBB
Cediranib
National Cancer Institute (NCI)
Phase 2BBB
Floxuridine
City of Hope Medical Center
Phase 2BBB

View all 49 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →